Monitoring cancer antigen 125 in serum of ovarian cancer patients after administration of 131I-labeled F(ab')2 fragments of OC125 antibody

1993 ◽  
Vol 39 (5) ◽  
pp. 891-896 ◽  
Author(s):  
J Reinsberg ◽  
B Schultes ◽  
U Wagner ◽  
D Krebs
Keyword(s):  
Ovarian Cancer ◽  
Enzyme Immunoassay ◽  
Cancer Patients ◽  
False Positive ◽  
Repeated Administration ◽  
Ca 125 ◽  
Cancer Antigen 125 ◽  
Serum Samples ◽  
Cancer Antigen ◽  
Apparent Increase

Abstract We evaluated the effect of repeated administration of OC125 F(ab')2 fragments on cancer antigen (CA) 125 determination in 210 serum samples from 30 patients. We found falsely high CA 125 concentrations in 142 (68%) samples, using a homologous CA 125 enzyme immunoassay (EIA) with OC125 antibodies. The Truquant OV2 method, which involves two other murine antibodies, and the IMx CA 125 method, which uses sheep antibodies as capture antibodies, resulted in only slightly increased (false-positive) values in some samples with exceptionally high CA 125 EIA values. We measured falsely low CA 125 values in 37 (18%) samples with the Truquant OV2 method. Interferences could be eliminated by removal of serum IgG. Our results suggest that interferences are to some extent caused by anti-idiotypic IgG induced by OC125 administration. Assays involving nonmurine anti-CA 125 antibodies as capture antibodies seem to be most suited for CA 125 determination after OC125 treatment, but in every case an apparent increase of CA 125 after OC125 infusion should be validated.

OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures.

1993 ◽  
Vol 11 (8) ◽  
pp. 1506-1510 ◽  
Author(s):  
F J Xu ◽  
Y H Yu ◽  
L Daly ◽  
K DeSombre ◽  
L Anselmino ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Elevated Serum ◽  
Ca 125 ◽  
Serum Samples ◽  
Persistent Disease ◽  
Second Look ◽  
Normal Individuals ◽  
Positive Results ◽  
Apparently Healthy

PURPOSE At second-look surgical surveillance procedures, normal CA-125 levels can be associated with persistent disease in 50% to 60% of patients. A novel radioimmunoassay (RIA) has been evaluated for the ability to identify patients with persistent disease who have normal levels of CA-125. MATERIALS AND METHODS The OVX1 double-determinant assay used a murine monoclonal antibody to detect an epitope on a high-molecular weight mucin-like glycoprotein. RESULTS Apparently healthy individuals had serum OVX1 levels of 2.23 +/- 2.48 U/mL (mean +/- SD). Elevated serum OVX1 levels (> 7.2 U/mL) were found in 5% of 184 normal individuals and in 70% of 93 epithelial ovarian cancer patients with clinically evident disease. Among sera from these ovarian cancer patients, OVX1 was elevated in 68% of 76 samples with CA-125 levels more than 35 U/mL and in 76% of 17 samples with CA-125 levels less than 35 U/mL. In serum samples obtained at the time of positive second-look laparotomy, 59% of 41 patients with CA-125 levels less than 35 U/mL had elevated OVX1 antigen levels, whereas 41% of 22 patients with CA-125 levels more than 35 U/mL had elevated serum OVX1 levels. In patients with negative second-look laparotomies, false-positive results were eliminated by increasing the threshold of OVX1 to 10.5 U/mL. At this level, 32% of 41 patients with positive second-look operations had an elevated OVX1 level, despite a normal CA-125 level. When used in combination, CA-125 (> 35 U/mL) and OVX1 (> 10.5 U/mL) detected persistent disease in 56% of 63 patients with positive surveillance procedures, compared with 35% when CA-125 was used alone (P < .05). CONCLUSION An elevated OVX1 level can alert oncologists to the possibility that ovarian cancer has persisted, despite the return of CA-125 to a normal range.

scholarly journals Immunohistochemical Study of CA 125 in Surface Epithelial Tumors of Ovary in Correlation with Serum Levels

2020 ◽  
Vol 7 (7) ◽  
pp. A355-360
Author(s):  
Karishma Pillarisetty ◽  
Savithri Ravindra
Keyword(s):  
Ovarian Cancer ◽  
Ovarian Neoplasms ◽  
Serum Levels ◽  
Tissue Expression ◽  
Epithelial Differentiation ◽  
Ca 125 ◽  
Cancer Antigen 125 ◽  
Cancer Antigen ◽  
Epithelial Tumors ◽  
Wide Range

Background: Ovarian carcinoma is the 4th leading cancer among women in India. Primary ovarian neoplasms exhibit a wide range of histopathological patterns and tumors with epithelial differentiation are most frequent. Among malignant tumors, most common histological type is serous adenocarcinoma whose diagnosis is established in advanced stages of disease in approximately 75% of patients. The most widely used tumor marker in ovarian cancer, often considered “gold standard” is Cancer Antigen125. Cancer Antigen 125 is a high molecular weight glycoprotein which is raised in approximately 90% of patients with advanced epithelial ovarian cancer.   Methods: A 2 year prospective study included 81 cases of ovarian neoplasms with surface epithelial differentiation.  The specimens were fixed in 10% formalin, routinely processed. Sections of 4-5 microns thickness were obtained from the paraffin block and stained with Hematoxylin & Eosin. The tumors were categorised according to WHO classification.  Immunohistochemical analysis of Cancer Antigen 125 was done in all malignant & borderline tumors.   Result: A total of 81 cases were studied. There were 15 cases with elevated serum Cancer Antigen 125 levels. Of these 8 showed positive tissue expression. The sensitivity of serum Cancer Antigen 125 was 68.75% & its specificity was 93.8%.   Conclusion: Serum Cancer Antigen 125 is elevated in ovarian tumors especially in malignant surface epithelial tumors & more commonly in serous cystadenocarcinoma. There was a good correlation between serum levels & tissue expression of Cancer Antigen 125.

scholarly journals High Serum Levels of Follistatin in Patients with Ovarian Cancer

2012 ◽  
Vol 40 (3) ◽  
pp. 877-886 ◽  
Author(s):  
P Ren ◽  
F-F Chen ◽  
H-Y Liu ◽  
X-L Cui ◽  
Y Sun ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Healthy Subjects ◽  
Ovarian Tissue ◽  
Serum Levels ◽  
Tumour Marker ◽  
High Serum ◽  
Ca 125 ◽  
Ovarian Cysts ◽  
Cancer Antigen 125 ◽  
Serum Samples

OBJECTIVE: This study investigated the potential use of serum follistatin (FST) as a marker for ovarian cancer alongside serum cancer antigen-125 (CA-125). METHODS: Serum samples were collected from patients with ovarian cancer ( n = 45), benign ovarian cysts ( n = 40) or other cancers ( n = 100) and from healthy subjects ( n = 60) for the determination of FST and CA-125 levels using enzyme-linked immunosorbent assays. Expression of FST in ovarian tissue was investigated using immunohistochemical staining. RESULTS: Compared with healthy subjects and patients with benign ovarian cysts, serum FST and CA-125 levels were significantly increased in patients with ovarian cancer. Using the 95% confidence interval for the healthy subjects group as the cut-off value, tumour marker sensitivity and specificity in ovarian cancer were 53.3% and 97% for FST and 77.8% and 84% for CA-125, respectively. Tissue expression of FST protein was more pronounced in ovarian cancer than in normal ovary. CONCLUSIONS: The serum FST level was elevated in the peripheral blood of patients with ovarian cancer and has potential as a tumour marker for ovarian cancer diagnosis. It may be particularly useful when combined with CA-125 detection to reduce the number of false-positive results.

An enzyme immunoassay procedure for cancer antigen 125 evaluated.

1988 ◽  
Vol 34 (12) ◽  
pp. 2513-2516 ◽  
Author(s):  
K W Ryder ◽  
T O Oei ◽  
M T Hull ◽  
M M Sample
Keyword(s):  
Positive Result ◽  
Ovarian Carcinoma ◽  
Receiver Operating Characteristic ◽  
Enzyme Immunoassay ◽  
Operating Characteristic ◽  
Ca 125 ◽  
Decision Threshold ◽  
Cancer Antigen 125 ◽  
Cancer Antigen ◽  
Receiver Operating Characteristic Curves

Abstract The performance of a new enzyme immunoassay (EIA) procedure (Abbott Labs.) for cancer antigen 125 (CA 125) met or exceeded the manufacturer's claims for all analytical variables examined. Overall correlation with results obtained with a radioimmunoassay (RIA) were good. However, near the decision thresholds typically chosen to define a positive result for ovarian carcinoma, EIA results were 10 to 20 arbitrary units/mL less than the RIA results. At specific decision thresholds, therefore, the sensitivities and specificities of the EIA and RIA procedure differed. Adjusting the decision thresholds gave a similar optimum efficiency for each procedure: EIA, 82.9% (decision threshold, 35 units/mL); RIA, 83.4% (decision threshold, 54 units/mL). Receiver-operating characteristic curves showed that the two procedures' ability to distinguish patients with active ovarian carcinoma from those with disease in remission was the same.

scholarly journals Secretome Identifies Tenascin-X as a Potent Marker of Ovarian Cancer

2015 ◽  
Vol 2015 ◽  
pp. 1-9 ◽  
Author(s):  
Marianne Kramer ◽  
Sandra Pierredon ◽  
Pascale Ribaux ◽  
Jean-Christophe Tille ◽  
Patrick Petignat ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Cells ◽  
Cancer Patients ◽  
Ca 125 ◽  
Ovarian Cancer Cells ◽  
Serous Ovarian Cancer ◽  
Protein Biomarkers ◽  
Serum Samples ◽  
Cancer Tissues

CA-125 has been a valuable marker for the follow-up of ovarian cancer patients but it is not sensitive enough to be used as diagnostic marker. We had already used secretomic methods to identify proteins differentially secreted by serous ovarian cancer cells compared to healthy ovarian cells. Here, we evaluated the secretion of these proteins by ovarian cancer cells during the follow-up of one patient. Proteins that correlated with CA-125 levels were screened using serum samples from ovarian cancer patients as well as benign and healthy controls. Tenascin-X secretion was shown to correlate with CA-125 value in the initial case study. The immunohistochemical detection of increased amount of tenascin-X in ovarian cancer tissues compared to healthy tissues confirms the potent interest in tenascin-X as marker. We then quantified the tenascin-X level in serum of patients and identified tenascin-X as potent marker for ovarian cancer, showing that secretomic analysis is suitable for the identification of protein biomarkers when combined with protein immunoassay. Using this method, we determined tenascin-X as a new potent marker for serous ovarian cancer.

Placental alkaline phosphatase and cancer antigen 125 in sera of patients with benign and malignant diseases.

1985 ◽  
Vol 31 (5) ◽  
pp. 687-690 ◽  
Author(s):  
M W Eerdekens ◽  
E J Nouwen ◽  
D E Pollet ◽  
T W Briers ◽  
M E De Broe
Keyword(s):  
Ovarian Cancer ◽  
Alkaline Phosphatase ◽  
Renal Dialysis ◽  
Ca 125 ◽  
Diabetic Patients ◽  
Placental Alkaline Phosphatase ◽  
Cancer Antigen 125 ◽  
Cancer Antigen ◽  
Human Placental Alkaline Phosphatase ◽  
Ovarian Neoplasia

Abstract Human placental alkaline phosphatase (hPLAP; EC 3.1.3.1), cancer antigen 125 (CA 125), and carcinoembryonic antigen (CEA) were determined in sera of patients with malignant and nonmalignant disorders. For CA 125 we used two different commercial assay systems, based on the same monoclonal antibody. hPLAP had the same sensitivity (20%) as CA 125 for detecting non-ovarian neoplasia, whereas that of CEA was 45%. For detecting ovarian cancer CA 125 (Cis kit) was slightly more sensitive (50%) than hPLAP (45%), much more than CEA (10%). hPLAP was increased in sera of 2% of patients with nonmalignant disorders, CA 125 in 23%, and CEA in 18%. hPLAP was increased in only one of 10 diabetic patients and two of 50 patients on chronic renal dialysis. CA 125 and CEA were respectively increased in 45% and 23% of all liver pathologies studied and in 12% and 17% of patients with renal insufficiency. The sensitivity of hPLAP for detecting ovarian cancer is slightly inferior to that of CA 125, but its specificity is much higher. We found the Abbott system for CA 125 to be more sensitive than the Cis system.

scholarly journals Validity of Cancer Antigen-125 (CA-125) and Risk of Malignancy Index (RMI) in the Diagnosis of Ovarian Cancer

2015 ◽  
Vol 30 (6) ◽  
pp. 428-434 ◽  
Author(s):  
Khawla Al-Musalhi ◽  
Manal Al-Kindi ◽  
Fatma Ramadhan ◽  
Thuraya Al-Rawahi ◽  
Khalsa Al-Hatali ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Ca 125 ◽  
Cancer Antigen 125 ◽  
Cancer Antigen ◽  
Risk Of Malignancy ◽  
Risk Of Malignancy Index

scholarly journals A Struma Ovarii Associated with Pseudo-Meigs’ Syndrome is Misdiagnosed as Advanced Ovarian Cancer: A Case Report

2021 ◽  
Vol 14 (9) ◽  
Author(s):  
Sedigheh Ghasemian Dizaj Mehr ◽  
Hale Ayatollahi ◽  
Afshin Mohammadi ◽  
Siamak Naji Haddadi ◽  
Farzaneh Rashidi Fakari
Keyword(s):  
Ovarian Cancer ◽  
Frozen Section ◽  
Thyroid Tissue ◽  
Advanced Ovarian Cancer ◽  
Final Diagnosis ◽  
Ca 125 ◽  
Struma Ovarii ◽  
Cancer Antigen 125 ◽  
Cancer Antigen ◽  
Case Presentation

Introduction: A struma ovarii is a benign monodermal teratoma, composed of mature thyroid tissue. The presentation of this disease with pseudo-Meigs’ syndrome [characterized by ascites, pleural effusions, and elevated cancer antigen-125 (CA-125) levels] may result in an advanced ovarian cancer misdiagnosis. Case Presentation: The patient was a 54-year-old woman with dyspnea, abdominal distention, and pseudo-Meigs’ syndrome. She had a final diagnosis of struma ovarii, misdiagnosed as advanced ovarian cancer. She is currently asymptomatic (after surgery) and has a normal CA-125 level. Conclusions: The preoperative diagnosis of struma ovarii is difficult, and if it presents with pseudo-Meigs’ syndrome, it may be initially misdiagnosed as advanced ovarian cancer. Using the frozen-section procedure, unnecessary extensive surgeries can be prevented.

Sign in / Sign up

Export Citation Format

Share Document